CD33 and hepatic veno-occlusive disease: In the light of this target, Mylotarg, a CD33-specific antibody–calicheamicin conjugate was first approved for CD33-positive pediatric AML treatment in 2000, while it was unfortunately withdrawn from the market in 2010 due to safety concerns such as those relating to the incidence of hepatic veno-occlusive disease, increased mortality and others [32].